Search research articles
Contact Us
Filters
Showing results (321-330 of 408) with videos related to
Page
of 41
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 2023
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies
Michael C Heinrich, Xinhua Zhang, Robin L Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Lancet (London, England)
|
February 15, 2016
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant Chawla, Robert G Maki, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2019
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma
Joerg T Hartmann, Hans-G Kopp, Viktor Gruenwald, et al.
JAMA Oncology
|
May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
BMC Cancer
|
December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Patrick Schöffski, Suzanne George, Michael C Heinrich, et al.
Epilepsia
|
July 5, 2017
Neuroinflammatory targets and treatments for epilepsy validated in experimental models
Eleonora Aronica, Sebastian Bauer, Yuri Bozzi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L Jones, César Serrano, Margaret von Mehren, et al.
Frontiers in Immunology
|
May 28, 2026
HDAC7 controls anti-viral and anti-tumor immunity by CD8<sup>+</sup> T cells
Cansu Yerinde, Jacqueline Keye, Hsiang-Jung Hsiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
Page
of 41
Search research articles
Search
Showing results (321-330 of 408) with videos related to
Sort By:
Page
of 41
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 2023
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies
Michael C Heinrich, Xinhua Zhang, Robin L Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Lancet (London, England)
|
February 15, 2016
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant Chawla, Robert G Maki, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2019
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma
Joerg T Hartmann, Hans-G Kopp, Viktor Gruenwald, et al.
JAMA Oncology
|
May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
BMC Cancer
|
December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Patrick Schöffski, Suzanne George, Michael C Heinrich, et al.
Epilepsia
|
July 5, 2017
Neuroinflammatory targets and treatments for epilepsy validated in experimental models
Eleonora Aronica, Sebastian Bauer, Yuri Bozzi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L Jones, César Serrano, Margaret von Mehren, et al.
Frontiers in Immunology
|
May 28, 2026
HDAC7 controls anti-viral and anti-tumor immunity by CD8<sup>+</sup> T cells
Cansu Yerinde, Jacqueline Keye, Hsiang-Jung Hsiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
Page
of 41